<DOC>
	<DOCNO>NCT01836796</DOCNO>
	<brief_summary>Recent data suggest trillion bacteria gastrointestinal tract ( gut microbiota ) function environmental factor modulates amount body fat . Obese individual alter gut microbiota germ-free mouse resistant develop diet-induced obesity lower fast insulin glucose concentration show improve glucose tolerance . Administration probiotic bacterium Lactobacillus Gasseri SBT2055 ferment milk 12 week reduce adiposity body weight obese adult possibly reduce lipid absorption inflammatory status . However , control study investigator knowledge address whether probiotic supplementation affect glucose metabolism . The investigator hypothesis supplementation Lactobacillus reuteri DSM 17938 may improve metabolic control type 2 diabetes patient . In addition , investigator explore possible mechanism behind antihyperglycemic action Lactobacillus Reuteri .</brief_summary>
	<brief_title>Metabolic Effects Lactobacillus Reuteri DSM 17938 Type 2 Diabetes</brief_title>
	<detailed_description>This double-blind , placebo control randomise study three parallel group type 2 diabetes ( T2D ) patient receive either placebo , Lactobacillus reuteri DSM 17938 , 1 x 108 ( colony-forming unit ) CFU Lactobacillus reuteri DSM 17938 CFU 1 x 1010 . The study perform Clinical Trial Centre ( CTC ) Sahlgrenska University Hospital Gothenburg . The investigator recruit forty-five T2D patient gender 50-75 yr , waist circumference &gt; 80 cm &gt; 94 cm woman men , respectively , HbA1c 50-90 mmol/mol treatment achieve normoglycemia lifestyle , insulin without oral hypoglycemic agent . Patients meet inclusion criterion ask join study give full write information study ask sign write consent form . Recruited patient undergo baseline examination collection demographic data , fast blood urine sample measurement blood pressure . After less three week , patient return 1.5 day investigation . At baseline , urine , blood faeces sample take also body composition assess ( Dual Energy X-ray Absorbtion ) DEXA , proton magnetic resonance spectroscopy quantify liver fat content , magnetic resonance imaging ( MRI ) determination visceral adipose tissue subcutaneous adipose tissue area level L4-L5 , euglycemic hyperinsulinemic clamp 120 milliunits ( mU ) /m2/min finally conjunction glucose clamp , indirect calorimetry , pulse wave analysis abdominal subcutaneous needle biopsy . At visit 3 glucose clamp , day 0 , patient randomize give study medication whole study period instruction take one dose per day ( morning breakfast ) . Patients return day 28 day 56 urine , faeces blood sample . After 12 week supplementation day 84±7 day , blood , urine faeces sample procedure perform baseline conjunction day 0 repeat . Moreover , patient return study medication use . Finally , patient complete study ask book visit ordinary diabetes team .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes duration &gt; 6 month Adults 50 75 year age Abdominal obesity ( female waist &gt; 80 cm ; male waist &gt; 94 cm ) HbA1c 5090 mmol/mol Antihyperglycemic treatment lifestyle , oral agent insulin Written inform consent Stated availability throughout study period Fasting Cpeptide &gt; 0.27 nmol/l BMI 2540 kg/m2 Stable weight ( ± 5 kg ) HbA1c ( ± 5 mmol/mol ) 6 month Autoimmune diabetes eg type 1 diabetes Psychiatric illness e g claustrophobia alcoholism , cancer diagnosis foreseeable need treatment corticosteroid antibiotic 12 week study period Heavy nicotine user suggest abstinence problem clamp Anticoagulation warfarin Ischemic heart disease event &lt; 6 month ago Inflammatory bowel disease Administration antibiotics 4 week inclusion Administration probiotic 2 week inclusion Participation clinical trial Other medical condition , judge screening doctor , might jeopardize compliance protocol eg severe obesity interfere access peripheral vein Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>